Motivation Intratumoral heterogeneity drives cancer recurrence and metastasis, yet single-cell drug response prediction faces severe “cross-domain” challenges, such as applying in vitro models to in vivo tissues or inferring metastatic resistance from primary tumors. These scenarios trigger distribution shifts arising from heterogeneous sequencing platforms, distinct tissue microenvironments, and metastatic evolution—problems rarely addressed by existing methods. Results We introduce CSGDA, a cell state-guided graph domain adaptation framework designed to predict drug responses across these biological heterogeneities. CSGDA incorporates biological priors to map gene expression into functional cell states, guiding a structure learning module to construct robust cell topology. To mitigate distribution shifts, the model employs graph domain adaptation combined with a novel overlap penalty mechanism. Extensive benchmarks on five scRNA-seq datasets demonstrate that CSGDA outperforms the state-of-the-art method SSDA4Drug by approximately 6 percentage points in both ACC and AUPR. Beyond prediction accuracy, we employed integrated gradients to effectively pinpoint key genes involved in drug resistance within a challenging cross-metastasis cisplatin dataset. These findings underscore CSGDA’s superior performance in single-cell drug response prediction and its potential in resolving single-cell heterogeneity, paving the way for precision medicine. Availability and Implementation Source code is available at https://github.com/yanfen-git/CSGDA-code and archived at https://doi.org/10.5281/zenodo.21759274. Data are available at https://doi.org/10.5281/zenodo.21770737. Supplementary Information Supplementary data are available at Bioinformatics online.
No takes yet. Share an insight, caveat, or question.
Fen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: